

CHERYL L. THOMPSON, PHD

SEPTEMBER 14, 2020

EDUCATION

Post-doctoral Fellowship	Computational Genomic Epidemiology of Cancer 2007-2009
PhD	Genetic and Molecular Epidemiology 2003-2007
MS	Computer Science Case Western Reserve University 2001-2003
BSE	Computer Engineering Case Western Reserve University 1994-2000 (co-op, part time)

PROFESSIONAL APPOINTMENTS

Position/Rank:	Assistant Dean of Educational Initiatives (50% effort) Director of Master's Programs (former title)
Institution/Department:	Case Western Reserve University School of Medicine
Dates:	April 2015-current <i>Provide overall strategic vision for new educational program development and leadership to both graduate educational initiatives and master's level programs in the School of Medicine. Work closely with Vice Dean of Research and Associate Dean of Graduate Education. Member of Office of Translation and Innovation. Select accomplishments to date include:</i> <ul style="list-style-type: none">• <i>Increased enrollment in revenue-generating Master's and post-bac Programs by over 400 students within 6 years (66% increase)</i>• <i>Development and implementation of new internship program (EnRICH) for master's and doctoral students at the CWRU School of Medicine, which includes development of partnerships with several local industry, non-profit, community and public health organizations</i>• <i>Design and development of PRIME – a new post-baccalaureate pre-medical program collaboratively developed with the College of Arts and Sciences; launched Fall 2017</i>• <i>Initiation and development of multiple professional development programs for SOM graduate students, ushered through accreditation process</i>• <i>Regular review of graduate (PhD and Master's) programs</i>• <i>Development and implementation of ExTEnd, a program to help train and give experience in post-secondary teaching to upper level graduate students and post-docs in the School of Medicine</i>• <i>Development, negotiation and initiation of multiple joint educational programs with Taipei Medical University, a strategic international partner</i>• <i>Increased online and hybrid courses offered in School of Medicine by >100%; developed training and incentive program for faculty</i>• <i>Provided advice and leadership throughout the development, approval and implementation of multiple additional master's and non-degree programs, including innovative learning opportunities and student assessment</i>• <i>Currently leading development of Doctorate of Physical Therapy (DPT) program via academic program development and faculty recruitment</i>• <i>Working with leadership across the University to develop an infrastructure, workflow, resources and faculty incentive to develop non-degree lifelong learning opportunities to engage students at all stages of their careers</i>

- *CWRU Translational Fellows Program (launched summer 2020) to educate doctoral students and post-docs on commercialization and entrepreneurship while translating CWRU technology into commercial ventures*

Position/Rank: Scientific PI, Breast Biorepository
 Institution/Department: Case Comprehensive Cancer Center
 Dates: 1/1/18-current
Provide overall scientific direction, strategic vision and evaluation/improvement for the Breast Biorepository effort within the Case Comprehensive Cancer Center; Recruitment and follow-up on over 200 patients to date.

Position/Rank: Member, Data Analytic Core, Clinical Research Core
 Institution/Department: Case Western Reserve University
 Dates: 9/1/16-current
Provide study design consultations and biostatistical support to numerous clinical faculty at CWRU affiliated hospitals. Covered 5% of salary in 2016, 4% of salary in 2017, 10% in 2018, 5% in 2019.

ACADEMIC APPOINTMENTS

Position/Rank: Associate Professor
 Institution/Department: Case Western Reserve University
 Department of Nutrition
 Member: Case Comprehensive Cancer Center
 Secondary Appointment: Population and Quantitative Health Sciences
 Dates: July 2018-current

Position/Rank: Assistant Professor
 Institution/Department: Case Western Reserve University
 Department of Nutrition
 Member: Case Comprehensive Cancer Center
 Secondary Appointment: Population and Quantitative Health Sciences
 Dates: December 2015-June 2018

Position/Rank: Assistant Professor
 Institution/Department: Case Western Reserve University
 Department of Family Medicine and Community Health
 Member: Case Comprehensive Cancer Center
 Secondary Appointment: Population and Quantitative Health Sciences
 Dates: January 2010-December 2015

Position/Rank: Senior Instructor
 Institution/Department: Case Western Reserve University
 Department of Family Medicine and Community Health
 Dates: January 2009-December 2009

HONORS AND AWARDS

1. American Society of Preventive Oncology Poster Presentation – 2nd Place, March 2014
2. National Institutes of Health Loan Repayment Program Awardee, 2010-2011
3. National Cancer Institute Transdisciplinary Research in Energetic and Cancer Centers Trainee Award for Excellence, June 2010
4. Selected to present research at the American Society of Preventive Oncology New Investigator's Workshop, March 2008
5. National Eye Institute Association for Research in Vision and Ophthalmology Annual Meeting Travel Grant, May 2005

MEMBERSHIP IN PROFESSIONAL SOCIETIES

1. Association of American Medical Colleges (AAMC), Group on Research Advancement and Development (GRAND) Affinity Group, 2020-present
2. Association of American Medical Colleges (AAMC), Graduate Research, Education and Training (GREAT) Affinity Group, 2020-present; PhD outreach committee member (2020-present)
3. Breast Cancer Association Consortium (BCAC), 2018-current; Confluence breast cancer genomics, 2019-current
4. InterMEL Melanoma Genomics Consortium, 2016-current
5. American Society of Preventive Oncology, Member, 2008-current
6. Alliance for Clinical Trials in Oncology Cooperative Group, Member, 2014-current, active in Health Disparities and Cancer Prevention groups
7. International Genetic Epidemiology Society, Member, 2004-2011
8. American Society of Human Genetics, Member, 2005-2013
9. American Association for the Advancement of Science, Member, 2005-2008
10. Association for Research in Vision and Ophthalmology, Member, 2004-2007

PROFESSIONAL DEVELOPMENT

1. Women in Leadership, Certificate, Weatherhead School of Management, CWRU, 2011
2. FLEX CWRU School of Medicine Women Faculty Professional Development Program, 2016-2017
3. Association of American Medical Colleges (AAMC) Leadership Development Workshop “Being a Resilient Leader”, Sept 5-6, 2018
4. HERS Leadership Institute, Colorado, June 8-20, 2020

PROFESSIONAL SERVICES

Manuscript Reviewing

Regular reviewer for several journals including JAMA Oncology, NEJM, BMC Cancer, Oncotarget, PloS One, etc.

Study Sections/Grant Review Committees

1. Section/Committee: NIH/NCI Special Emphasis Panel ZCA1 SRLB-D – Omnibus Epidemiology
Dates of Service: April 15-16, 2010
2. Section/Committee: NIH/NCI Special Emphasis Panel ZCA1 SRLB-D – Omnibus Epidemiology
Dates of Service: November 17-18, 2011
3. Section/Committee: NIH/NCI Special Emphasis Panel ZCA1 SRLB-D – Omnibus Epidemiology
Dates of Service: March 22-23, 2012
4. Section/Committee: NIH/NCI Special Emphasis Panel ZCA1 SRLB-D – Omnibus Epidemiology
Dates of Service: June 2012
5. Section/Committee: NIH/NCI Special Emphasis Panel ZCA1 SRLB-D – Omnibus Epidemiology
Dates of Service: July 18-19, 2013
6. Section/Committee: NIH/NCI Special Emphasis Panel ZCA1 SRLB-D – Omnibus Epidemiology
Dates of Service: November 7, 2013
7. Section/Committee: Department of Defense Breast Cancer Research Program, Detection, Diagnosis and Prognosis (DDP) Panel
Dates of Service: March 12-14, 2014
8. Section/Committee: NIH/NCI Special Emphasis Panel ZCA1 SRLB-D – Omnibus Epidemiology
Dates of Service: March 21, 2014
9. Section/Committee: NIH/NCI Special Emphasis Panel ZCA1 SRLB-D – Omnibus Epidemiology
Dates of Service: June 18, 2014
10. Section/Committee: NIH/NCI Special Emphasis Panel ZCA1 SRLB-D – Omnibus Epidemiology
Dates of Service: April 30, 2015
11. Section/Committee: Department of Defense Breast Cancer Research Program (BCRP)
Dates of Service: July 14, 2016
12. Section/Committee: NIH/NCI Special Emphasis Panel ZCA1 SRLB-D – Omnibus Epidemiology (R03/R21)
Dates of Service: June 5, 2017
13. Section/Committee: Department of Defense Congressionally Directed Medical Research Programs (CDMRP)
Dates of Service: December 3-5, 2017
14. Section/Committee: Department of Defense Breast Cancer Research Program (BCRP)

- Dates of Service: July 29-30, 2018
15. Section/Committee: Department of Defense Peer-Reviewed Cancer Research Program (CDMRP)
 Dates of Service: November 28-29, 2018
16. Section/Committee: NIH/NCI Program Project IV (P01) – P01 applications for the National Cancer Institute
 Dates of Service: June 6-7, 2019
17. Section/Committee: Department of Defense Breast Cancer Research Program (BCRP)
 Dates of Service: May 28-29, 2020

COMMITTEE SERVICE

National

1. Organization: American Society of Preventive Oncology
 Committee Name/Role: Executive Committee
 Dates of Service: 2017-2020 Secretary/Treasurer (elected position); 2012-2014 Early Career Development Special Interest Group Chair; Community and Science Buddy Program scientific participant 2020-current
2. Organization: American Society of Preventive Oncology
 Committee Name/Role: Chair All Level Career Development Task Force
 Dates of Service: 2012-2017
Led development of career development webinar series for ASPO members and other investigators
3. Organization: American Society of Preventive Oncology
 Committee Name/Role: Annual Meeting Program Committee Member
 Dates of Service: 2012, 2014
4. Organization: Alliance for Clinical Trials in Oncology Cooperate Group
 Committee Name/Role: Health Disparities Committee Member
 Dates of Service: 2014-2019
5. Association of American Medical Colleges (AAMC), Graduate Research, Education and Training (GREAT) Affinity Group
 Committee Name/Role: PhD Outreach Committee Member
 Dates of Service: 2020-current

Local

1. Committee Name/Role: Chair, Populations Studies Focus Group, Breast Cancer Program, Case Comprehensive Cancer Center
 Dates of Service: 2013-2015
2. Committee Name/Role: CWRU School of Medicine Dean's *Ad Hoc* Faculty Award Advisory Committee
 Dates of Service: 2012-2016
3. Committee Name/Role: CWRU Physician Assistant Program Admissions application reviewer and interviewer
 Dates of Service: 2015-current
4. Committee Name/Role: CWRU School of Medicine *Ad Hoc* Graduate Programs Committee
 Dates of Service: 2015-current
This committee reviews and approves new courses and changes to courses within the School of Medicine
5. Committee Name/Role: School of Medicine Curriculum Committee
 Dates of Service: 2015-current
6. Committee Name/Role: Asst/Assoc Professor Faculty Search Committee Chair, Department of Nutrition
 Dates of Service: February 2016-June 2015
7. Committee Name/Role: Asst/Assoc Professor Faculty Search Committee Chair, Department of Nutrition
 Dates of Service: October 2016-March 2017

8. PI of Case Comprehensive Cancer Center Breast Cancer Biorepository
 Dates of Service: November 2015-current
Developed comprehensive IRB protocol and system for cancer center-wide collection of blood, tissue and creation of patient-derived xenograph models of breast cancer patients and controls along with well annotated clinical data. Recruitment began November 2016.
9. Committee Name/Role: Assistant Professor Faculty Search Committee Member, Department of Urology
 Dates of Service: April 2017-April 2018
10. Committee Name/Role: Assistant Professor Faculty Search Committee Member, Physician Assistant Program
 Dates of Service: April 2017-June 2017
11. Committee Name/Role: Part-time Assistant Professor Faculty Search Committee Member, Physician Assistant Program
 Dates of Service: January 2018-April 2018
12. Committee Name/Role: Co-Chair, Doctorate of Physical Therapy Program Director Search Committee
 Dates of Service: March 2018-current
13. Committee Name/Role: University Classroom Evaluation and Planning Committee
 Dates of Service: June 2018-December 2019
14. Committee Name/Role: Chair, Systems Biology and Bioinformatics New Faculty Member Search Committee
 Dates of Service: June 2018-November 2019
15. Committee Name/Role: Medical Director, Physician Assistant Program Search Committee
 Dates of Service: August 2018-December 2018
16. Committee Name/Role: Reviewer, Clinical and Translational Science Collaborative (CTSC) Core Utilization Pilot Grant Program Grant Review Committee
 Dates of Service: September 2018-current
17. Committee Name/Role: Laura and Alvin Siegal Lifelong Learning Program Faculty Advisory Committee
 Dates of Service: January 2019-current
18. Committee Name/Role: Academic Coordinator, Physician Assistant Program Search Committee
 Dates of Service: April 2019-Jan 2020
19. Committee Name/Role: Chair, Department of Nutrition Research Faculty Search Committee (3 positions)
 Dates of Service: June 2019-current

Educational Committees

1. Committee Name/Role: CWRU School of Medicine Curriculum Committee
 Dates of Service: May 2015-June 2018; Chair, July 2018-current
This commitment reviews and approved new undergraduate and graduate courses within the School of Medicine
2. Committee Name/Role: CWRU School of Medicine *Ad Hoc* Graduate Program Review Committee
 Dates of Service: June 2015-current
This committee reviews and approves new graduate (master's, doctoral, certificate) programs and changes to programs within the School of Medicine
3. Committee Name/Role: Physician Assistant Education Policy Committee
 Dates of Service: October 2017-current
This committee is charged with reviewing new program policy as it is developed and undergoing changes and conduct a yearly review of all PA program manuals.

TEACHING ACTIVITIES

Curriculum/Course Development and Teaching

1. MGRD 310/410 – Clinical Inquiry (IQ): A 3 credit graded graduate course designed for pre-med undergraduate and master’s students to expose them to clinical cases and the IQ process. Instruction model based on our award-winning MD curriculum IQ program. Development: June-December 2015. Taught when first offered in Spring 2016 (11 students) and Fall 2017 (14 students).
2. MGRD 610 – Internship in Biomedical Sciences: a non-graded experiential learning course for graduate students in the School of Medicine. This mechanism allows students participating in the EnRICH internship program doing substantial internships in biomedical research to get academic credit for it. Developed October 2015 –March 2016. First offered Spring 2016 (2 students). Summer 2016 (1 student). Fall 2016 (3 students). Spring 2017 (3 students).
3. NTRN 529 – Nutritional Epidemiology: A three credit graduate course for Nutrition master’s students to get an introduction to epidemiology in the context of nutrition. Completely re-designed previously offered course; moved to online course in 2017. Fall 2016-current.
4. IBMS 450 – Biostatistics for Biomedical Scientists: Part of committee to design new introductory biostatistics course for incoming doctoral students in the School of Medicine. Development: July-August 2017.
5. MGRD 311/411 – Clinical Inquiry (IQ) II: A second semester of MGRD 310/410 designed to further cover additional topics not covered in first semester. Implemented in conjunction with launching of PRIME program for 2017-2018 academic year. Development May 2017-January 2018, first offered Spring 2018.
6. NTRN 562 – Student research preceptor for Emily Yarcusko (Spring 2018).
7. IBMS 500 – Small group discussion facilitator (1 session Spring 2017, 1 session Spring 2018).
8. NTRN 601 – Independent study with Emily Yarcusko (Fall 2018).
9. MGRD 425 – Leadership and Professional Development Skills for Biomedical Sciences. Developed 0 credit workshop based course focused on key skills needed to be successful leaders in the biomedical and health science fields.

Educational Program Development

1. Post-Baccalaureate Readiness for Medical Education (PRIME): Led the initiation and collaborative development of PRIME program with the College of Arts and Sciences. This program is a non-degree undergraduate class based program that is a result of a collaboration between the School of Medicine and the College of Arts and Sciences. This is an exceptional program for two types of post-bac students who are interested in medical school: career changers (or students who had not originally planned on medical school and thus did not take all the requirements) and academic enhancers (who do not have a strong enough undergraduate GPA to be competitive at high ranking medical schools). First class enrolled Fall 2017.
2. Enhancing Research and Industry Career Horizons (EnRICH): Led the development, initiation and growth of internship and career exposure program for School of Medicine graduate students. Facilitated experiences for more than 60 students to date. Currently serve as faculty contact and lead.
3. Graduate Student Professional Development Program: Led the development and initiation of the Graduate Student Professional Development Program at the CWRU School of Medicine. This extra-curricular program for graduate (Master’s and Doctoral) students helps them develop teamwork, leadership, creativity, problem solving and communication skills critical to a career in any aspect of biomedical sciences and health care. First cohort participated Spring 2018, two additional since then.
4. Doctorate of Physical Therapy (DPT): Leading the initiation and development of DPT program within the CWRU School of Medicine. Leading an advisory committee of DPTs from our clinical affiliates, researchers in physical therapy and rehabilitation from various Department in CWRU, and a DPT program consultant to develop an innovative program and curriculum building on our strengths in education as well as research. Current status: Program has received School of Medicine and University approval. In recruitment of program director, paused pending new Dean of School of Medicine and new Vice Dean of Medical Education starting 7/1/20.

Medical Student Teaching

1. Inquiry Group (IQ) Facilitator: Block 3 2010; Block 2 2011; Block 3; Block 5 2012; Block 2; Block 6 2014; Block 3 second half 2012/13– overall average 60 contact hours yearly to 8-9 students, overall course rating 4.8/5.
2. Inquiry Group (IQ) Substitute Facilitator: 2013-2014 -10 sessions (50 hours); 2015 - 4 sessions (20 hours), 2016 - 6 sessions (30 hours), 2017 – 10 sessions (50 hours), 2018 – 6 sessions (30 hours), 2019—14 sessions.
3. Cleveland Clinic Lerner College of Medicine – Year 2 Journal Club Content Expert – 9/1/2017, 8/10/2018.

Course Lectures

1. “Introduction to Genetic Epidemiology”, Pediatric Psychology Graduate Student Seminar, Fall 2012, Fall 2013

2. “Research in Epidemiology”, DENT 501 seminar series, Spring 2011, Spring 2012
3. “Breast Cancer Epidemiology”, EPBI 497: Cancer Epidemiology, Guest Speaker, Fall 2010
4. “K-awards for lunch”, Office of Graduate Studies Professional Skills Program, Fall 2009
5. “Writing an NIH Career Development Award”, Office of Graduate Studies Professional Skills Program, Spring 2009.
6. “Bootcamp in Medical Genetics”, Cleveland State University – Northeast Ohio Medical University, Partnership for Urban Health, June 2018, June 2019.

Invited Lectures

Local/Regional:

1. “Retinol Binding Protein-4 and Colon Neoplasia”. Transdisciplinary Research in Energetics and Cancer Scientific Seminar, March 20, 2008.
2. “Careers in Genetics Research”, Nordonia High School DNA Day, April 25, 2008.
3. “Genetic Variation and Risk of Type II Diabetes and Obesity”. Transdisciplinary Research in Energetics and Cancer Scientific Seminar, September 25, 2008.
4. “Mammographic Density and Risk of Breast Cancer”. Department of Radiology Grand Rounds, November 17, 2009.
5. “Activation of the PI3K Pathway in Breast and Colon Cancer”. Case Comprehensive Cancer Center Scientific Series, January 28, 2010.
6. “Nutrition and Breast Cancer”. University Hospitals MacDonald’s Women’s Health Leadership Council, Guest Speaker, September 23, 2010.
7. “Epidemiology of MicroRNAs and Breast Cancer”. Case Comprehensive Cancer Center Seminar Series. March 11, 2011.
8. “Epidemiology of Mammographic Density”. Case Comprehensive Cancer Center Scientific Series. May 31, 2012.
9. “Identifying Biomarkers of Cancer using Next Generation Sequencing”. Case Comprehensive Cancer Center Sequencing Data Interest Group. November 5, 2012.
10. “Breast Cancer Epidemiology and Screening”, Department of Family Medicine and Community Health Resident Didactic Lectures, December 5, 2012.
11. “Sleep and Cancer Risk”, Sleep Grand Rounds, University Hospitals Case Medical Center, January 8, 2013.
12. “Sleep and Cancer Risk”, Sleep Medicine Grand Rounds, Cleveland Clinic, January 31, 2013.
13. “Sleep and Cancer”, School of Nursing Seminar Series, Case Western Reserve University, March 18, 2013.
14. “Breast Cancer Genetic Epidemiology”, Hathaway Brown High School, Shaker Heights, OH, January 31, 2014.
15. “Sleep and Breast Cancer Aggressiveness”, Sleep Medicine Grand Rounds, Cleveland Clinic, April 30, 2015.
16. “Sleep and Declines in Physical Activity as Contributors to Breast Cancer Disparities”, CCCC Retreat, July 14, 2015.
17. “The Connections between Sleep and Cancer: What you need to know”, CWRU Siegal Lifelong Learning, April 15, 2020.

National:

1. “Phosphatidylinositol 3-kinase Subunit Genetic Polymorphisms and Colon Cancer Risk”. Transdisciplinary Research in Energetics and Cancer Scientific Meeting, Minneapolis, MN, Oct 2007.
2. “Experiences as a Trainee in the Transdisciplinary Research in Energetics and Cancer (TREC) Program”. American Society of Preventive Oncology, Tampa, FL, March, 2009.
3. “Analysis of the Bronchoalveolar Carcinoma Progression Model using FFPE Specimens”. RNA Rustbelt Meeting, Dayton, OH, October 20, 2012.
4. “MicroRNAs in Obesity and Postmenopausal Breast Cancer”. American Society of Human Genetics (ASHG) 2012, San Francisco, CA, November 10, 2012.
5. “Sleep and Breast Cancer Phenotype”, Penn State University Cancer Institute, Hershey, PA, February 10, 2015.
6. “Sleep and Breast Cancer Phenotype”, Boston University, Boston, MA, February 18, 2015.
7. “Sleep and Breast Cancer Aggressiveness”, University at Buffalo, Buffalo, NY, March 25, 2016.
8. “Sleep and Breast Cancer Aggressiveness”, Great Lakes Breast Cancer Symposium, Pittsburgh, PA, September 10, 2016.
9. “Translational Research in Cancer Epidemiology”, Kent State University, February 13, 2017.
10. “Sleep and Cancer Risk”, Cleveland Clinic Wake Up to Sleep Disorders Symposium, September 7-8, 2018.

International:

1. “Sleep and Breast Cancer Aggressiveness”, Taipei Medical University, Taipei, Taiwan, March 18, 2016.

Trainees / Mentees

Mentor in Case Venture Mentor Program 2018-current. Translational Research Mentor to 2 entrepreneur trainees.

Faculty research mentor for 5 junior faculty

Participant in the American Society of Preventive Oncology as a Junior Faculty Career Development Mentor

Medical student research mentor to 10 MD students (for summer semester and/or 4 month research block and/or research elective): Matthew Morton, 2011-2014, currently in fellowship year at Emory. *Awarded Brian Werbel Memorial Fund Trainee Award for Cancer Research. Published three manuscripts, graduated with Research Honors.*

PhD or Post-doctoral research mentor to 5 PhD/post-docs students

- Hanan Safar, PhD committee member, PhD in Nursing

Biostatistical mentor to 6 medical fellows

Master's level student research mentor and/or thesis committee member to 11 master's students

Undergraduate research advisor to 5 undergraduate students

High School Research Mentor to 11 high school students. Students with exceptional progress/awards:

1. Gavin Buck, *Selected as one of top 3 abstracts for presentation at Hawken Science Research Symposium.*
2. Matthew Thompson, *Awarded CWRU Treuhaft Scholarship – a highly competitive full scholarship for undergraduate science students, now a senior, will join an MD/PhD program in 2020 (currently deciding where)*
3. Sinead Li, *Winner of Intel Computer Science Award 2019, submitted first manuscript May 2019*

RESEARCH SUPPORT

Under Review

- | | |
|---|------------------|
| 1. R21 CA259638 | 1/1/21-12/31/22 |
| National Cancer Institute | \$275,000 direct |
| “Socioeconomic status, the exposome and epigenetic patterns in breast cancer patients” | |
| Role: PI | |
| <i>This investigates the association between socioeconomic status and neighborhood constructs with epigenetic patterns in both the circulation and breast tumors to identify patterns associated with specific exposures. This study will lay the foundation for further understanding the mechanisms behind the interplay between genetics and the environment on breast cancer development.</i> | |
| <i>Status: Pending review</i> | |
| 2. R01 | 1/1/21-12/31/25 |
| National Cancer Institute | |
| “Improved cancer treatment monitoring with digital PET/CT: Application to breast cancer” | |
| PI: Raymond Muzic, PhD | |
| Role: Co-I | |
| <i>This R01 develops digital PET/CT technology for monitoring treatment response among metastatic breast cancer patients. For this study, I provide clinical trial study design and biostatistical analysis and support.</i> | |
| <i>Status: Pending review</i> | |
| 3. R01 | 9/1/20-8/30/25 |
| National Cancer Institute | |
| “YES1 as a driver of triple negative breast cancer” | |
| PI: Ruth Keri, PhD | |
| Role: Co-I | |
| <i>This R01 studies the role of YES1 in driving the development and progression of triple negative breast cancer through EGFR. For this study, I provide population science expertise in helping to translate findings from this project into patient samples.</i> | |
| <i>Status: Scored in 8th percentile</i> | |

Current

1. R03 CA241956 7/1/20-6/30/22
National Cancer Institute \$100,000 direct
“Breast Cancer Risk Factors and Epigenetic Age Acceleration”
MPI: Cheryl Thompson, PhD (contact PI) and Fredrick Schumacher, PhD
Role: Co-PI
This investigates the association between known breast cancer risk factors and epigenetic age acceleration as a potential mediator of breast cancer disparities.

2. Case Comprehensive Cancer Center – Innovation Pilot 7/1/20-6/30/21
“Extracellular Vesicles for the Early Detection of Breast Cancer” \$75,000 direct
PI: Cheryl Thompson, PhD
Role: PI
This pilot project will look at the feasibility of using extracellular vesicles and associated HERV proteins for the early detection of breast cancer.

3. P30 CA043703 9/01/18-8/31/19 (in no cost extension)
National Cancer Institute
“Contribution of Gynecologic and Breast Cancer Specimens”
PI: Stefanie Avril, MD
Role: Co-investigator
This is an administrative supplement to the Case Comprehensive Cancer Center P30 grant. This is one of a few nationally funded supplements to provide minority cancer specimens to an NCI repository as part of a larger effort to increase the availability of samples and data on minority cancer patients. In this project, our team will contribute samples from African American endometrial, ovarian and breast patients. As PI of the Breast Biorepository, with approximately 50% minority recruitment, I lead the efforts to collect and annotate samples from the breast patients.

4. University Hospitals Cleveland Medical Center Donor Funds 5/01/18-4/30/21
“Breast Cancer Biorepository” \$120,000 direct
Role: Principal Investigator
These fund support our efforts to build a biorepository of biospecimens and clinical data from breast cancer patients and high risk controls, with a focus on recruitment of minority patients. This biorepository supports the research efforts of dozens of Case Comprehensive Cancer Center members to propel their breast cancer research forward into clinical specimens.

5. RO1CA213843* 8/1/17-7/31/22
NIH/NCI
“Elucidating and Leveraging the mTOR Negative Feedback Pathway in Breast Cancer”
PI: Ruth Keri, PhD
Role: Co-investigator
As a team scientist, I provide expertise in biostatistics and clinical translational research.

6. P01CA206980 5/1/17-4/31/22
NIH/NCI
“Integration of Clinical and Molecular Biomarkers for Melanoma Survival”
“Project 1: Impact of Melanoma Genetic, Clinical and Immune Sub-classification on Survival”
PI: Marianne Berwick, University of New Mexico and Nancy Thomas, University of North Carolina Chapel Hill
Role: Site PI of Project 1 at CWRU, Co-Investigator Project 1
This P01 will jointly explore the genomic, methylation and transcriptomic changes in melanoma subtypes and will help support a new consortium (Inter-MEL) dedicated to exploring the genetics of melanoma.

7. RO1CA206505* 4/1/16-3/31/21
NIH/NCI
“BET Regulation of Triple Negative Breast Cancer”
PI: Ruth Keri, PhD
Role: Co-investigator
As a team scientist, I provide expertise in biostatistics and clinical translational research. In this project, I assist with the statistical analysis of data on the role of BET, JQ1 and related proteins on tumor growth and cell death in breast cancer cell lines.

8. R01CA196687* 9/1/15-8/30/20
 National Institutes of Health – NCI \$1.9M direct
 “Accurate MR-based PET Attenuation Correction for Quantitative Clinical Trials”
 PI: Raymond Muzic, PhD
 Role: Co-investigator
On this project, I have a team science role in the form of biostatistical support. This project looks at different models of correcting for attenuation in PET/MR imaging. On this project, I assist with the statistical analysis of the imaging data and statistical analysis of study hypotheses.

Past

9. BC150596* 4/1/16-3/31/19
 Department of Defense BCRP \$800,000 direct
 “Characterization of Clustered CTCs to Eliminate Breast Cancer Metastasis”
 PI: Huiping Liu and Alvin Schmaier
 Role: Co-investigator
As a team and translational scientist, I provide expertise in clinical biomarker study design. I worked closely with Dr. Liu on this study design to help articulate the most clinically relevant study design. Further, samples from my case-control study of breast cancer patients and controls provide well-annotated samples for this study crucial for its success.
10. N/A* 4/1/15-2/28/19
 The Char and Chuck Fowler Family Foundation \$1.25M direct over 5 years
 PI: Meg Gerstenblith, MD
 Role: Co-investigator
For this project, I provide expertise in genetic and molecular epidemiology. Part of this project is to build a biorepository of epidemiological risk factor survey, blood and tissue samples from melanoma patients. I lead all effort to recruit patients into this study and collect samples. A second aim of this study is to characterize melanoma in the University Hospitals patient population, and understand unique characteristics of adolescent and young adult melanoma patients. For this project, I provide expertise in epidemiological study design, and statistical analysis of the epidemiological features of the patients.
11. P30 CA043703 6/01/17-5/31/18
 National Cancer Institute
 “Breast Cancer Risk Factors and Epigenetic Age Acceleration”
 Co-PI of pilot grant: Cheryl Thompson, PhD, Fredrick Schumacher, PhD
 Role: Co-Principal Investigator of Pilot Grant
12. R01CA197780 * 4/1/16-3/31/21 (moved to U Michigan 7/1/18)
 NIH/NCI \$376,963 year 1
 “Examining the role of the miR-181a:Wnt/B-catenin axis in ovarian cancer recurrence” 5
 PI: Analisa DiFeo, PhD
 Role: Co-investigator
As a team scientist, I provide expertise in biostatistics and clinical translational research. In this project, I provide statistical analysis of functional studies of miR-181 cell line models as well as models investigating the potential role of targeting the Wnt signaling pathway for treatment in high grade serous ovarian cancer.
13. R21 HD081165* 7/1/14-6/30/16
 National Institutes of Health – NICHD \$375,000 direct
 “A Novel Regulator of Breast Development”
 PI: Ruth Keri, PhD
 Role: Co-investigator
For this project, I provide expertise in genetic and molecular epidemiology
14. 1P50CA150964 (Markowitz, Sanford, PI) 9/1/11-8/31/16
 National Cancer Institute about \$7M direct total
 “Case GI SPORE”
 PI: Sanford Markowitz, MD

Role: Co-investigator

For this project, I provide expertise in genetic and molecular epidemiology

15. N/A 7/1/14-6/30/15
Earlier.org – Friends for an Earlier Breast Cancer Test \$40,000 direct
PI: Cheryl Thompson, PhD
“Circulating RNAs for Early Detection of Breast Cancer”
Role: Principal Investigator
16. UL1 RR024989* 6/01/13-5/30/14
National Institutes of Health \$50,000 direct
“Evaluation of alpha-methylacyl-CoA as a non-invasive diagnostic biomarker for prostate cancer”
PI of pilot: Matthew Cooney, MD
Role: Co-I of pilot
For this project, I served in a collaborative role with expertise in clinical biomarker study design and biostatistical support.
17. Center for Genetic Research Ethics and Law (CGREAL) 3/1/14-7/31/14
NHGRI \$7,020 direct
“Translating Genetic Predictors of Treatment Toxicity into the Clinic”
PI of pilot grant: Patricia Marshall, PhD and Cheryl L Thompson, PhD
Role: Co-Principal Investigator of Pilot Grant
18. K07CA136758 8/01/09-7/31/14
National Cancer Institute \$602,885 direct
“Genetic variants in the PI3K pathway in mammographic density and breast cancer”
PI: Cheryl Thompson, PhD
Role: Principal Investigator
19. R01CA136726 9/01/09-8/30/14
National Cancer Institute \$2.0M direct
“Obesity-Related Insulin Resistance Signaling Pathway Factors and Colon Cancer” 5% effort
PI: Li Li, MD, PhD
Role: Co-investigator
20. NIH 3/1/13-7/31/12
Center for Genetic Research Ethics and Law (CGREAL) \$9,950 direct
“Returning Genetic Results from Research on Breast Cancer”
PI of pilot grant: Patricia Marshall, PhD and Cheryl L Thompson, PhD
Role: Co-Principal Investigator of Pilot Grant
21. UL1 RR024989 4/01/12-9/30/12
National Institutes of Health \$10,000 direct
“Sleep, Genetic Variants in Circadian Rhythm Genes and Breast Cancer”
PI of Pilot: Cheryl Thompson, PhD
Role: PI of core utilization pilot
22. R03CA143917 1/1/11-12/31/12
National Cancer Institute \$100,000 direct
“Longitudinal Changes in Mammographic Density”
PI: Li Li, MD, PhD
Role: Co- Investigator
23. P30 CA043703 12/01/10-11/30/11
National Cancer Institute \$30,000 direct
“A Biorepository for Research in Lung Cancer Risk, Detection and Prognosis”
PI of pilot grant: Cheryl Thompson, PhD
Role: Principal Investigator of Pilot Grant
24. UL1 RR024989 6/01/10-11/30/10

- National Institutes of Health \$10,000 direct
 “Genetics of Aberrant Breast Development”
 PI of core utilization grant: Cheryl Thompson, PhD
 Role: Principal Investigator of core utilization Grant
25. IRG-91-022-15 9/01/09-8/31/10
 American Cancer Society \$30,000 direct
 “Variation in Breast Tissue Gene Expression by Mammographic Density”
 Role: Principal Investigator of institutional review grant
26. U54 CA-116867 9/01/09-8/31/10
 National Cancer Institute \$50,000 direct
 “CASE Center for Transdisciplinary Research on Energetics and Cancer”
 Pilot Project: “Variation in Breast Tissue Gene Expression by Mammographic Density”
 PI: Cheryl Thompson, PhD
 Role: Principal Investigator of developmental project
27. 1 U54 CA-116867 9/01/08-8/31/09
 National Cancer Institute \$50,000 direct
 “CASE Center for Transdisciplinary Research on Energetics and Cancer”
 Pilot Project: “Effect of obesity and insulin resistance on the activation of IRS1, AKT and mTOR and the development of colon adenomas”
 PI: Cheryl Thompson, PhD
 Role: Principal Investigator of developmental project
28. 1 U54 CA-116867 10/1/07-9/30/08
 National Cancer Institute \$50,000 direct
 “CASE Center for Transdisciplinary Research on Energetics and Cancer”
 Pilot Project: “Retinol Binding Protein-4 (RBP4): A novel biomarker for colon neoplasia”
 PI: Cheryl Thompson, PhD
 Role: Principal Investigator of developmental project

**Team Science Collaborator: On these grants I served in a key role as the cancer translational researcher, and provide my expertise in clinical/epidemiology study design and data analysis to these projects.*

BIBLIOGRAPHY

Peer Reviewed Articles

1. **Thompson CL**, Baechle D, Lu Q, Mathew G, Song Y, Iyengar SK, Gray-McGuire C, Goddard KAB. Effect of Genotyping Error in Model-Free Linkage Analysis using Microsatellite or SNP Marker Maps. *BMC Genet.* 2005; 6 Suppl 1:S153.
2. **Thompson CL**, Rybicki BA, Iannuzzi MC, Elston RC, Iyengar SK, Gray-McGuire C and the SAGA Research Group. Reduction of Sample Heterogeneity Using Population Substructure: An Example from a Population of African-American Sarcoidosis Families. *Am J Hum Genet.* 2006; 79(4):606-613.
3. **Thompson CL**, Klein BEK, Klein R, Xu Z, Capriotti J, Joshi T, Leontiev D, Lee KE, Elston RC, Iyengar SK. Complement Factor H and Hemicentin-1 in Age-Related Macular Degeneration and Renal Phenotypes. *Hum Mol Genet.* 2007; 16(17):2135-2148.
4. **Thompson CL**, Jun G, Klein BEK, Klein R, Capriotti J, Lee KE, Iyengar SK. Genetics of Pigment Changes and Geographic Atrophy. *Invest Ophthalmol Vis Sci.* 2007; 48(7):3005-3013.
5. **Thompson CL**, Khiani V, Chak A, Berger NA, Li L. Trends in Carbohydrate Consumption and Esophageal Cancer. *Am J Gastro.* 2008; 103(3):555-61.
6. Li L, Plummer SJ, **Thompson CL**, Merkulova A, Acheson LS, Tucker TC, Casey G. A Common 8q24 Variant and Risk of Colon Cancer: A Population-Based Case-Control Study. *Cancer Epidemiol Biomarkers Prev.* 2008; 104(2):32-3.
7. Li L, Plummer S, **Thompson CL**, Tucker TC, Casey G. Association between Phosphatidylinositol 3-Kinase p85 α Regulatory Subunit *Met326Ile* Polymorphism and Colon Cancer Risk. *Clin Cancer Res.* 2008; 14(3):663-7.
8. Nock NL, **Thompson CL**, Tucker TC, Li L Associations Between Obesity and Changes in Body Mass Index Over Time and Colon Cancer Risk. *Obesity* 2008;16:1099-104.

9. Ochs-Balcom HM, Cicek MS, **Thompson CL**, Tucker TC, Elston RC, Plummer S, Casey G, Li L. Association of Vitamin D Receptor Variants, Adiposity and Colon Cancer. *Carcinogenesis* 2008; 29 (9):1788-1793. **(highly cited article)**
10. Stein CM, Zalwango S, Malone LL, Won S, Mayanja-Kizza H, Mugerwa RD, Leontiev DV, **Thompson CL**, Cartier KC, Elston RC, Iyengar SK, Boom WH, Whalen CC. Genome Scan of *M. tuberculosis* Infection and Disease in Ugandans. *PLoS One* 2008; 3 (12):e4094. **(highly cited article)**
11. **Thompson CL**, Plummer SJ, Acheson LS, Tucker TC, Casey G, Li L. Association of common genetic variants in SMAD7 and risk of colon cancer. *Carcinogenesis* 2009; 30(6):982-6.
12. **Thompson CL**, Plummer SJ, Merkulova A, Cheng I, Tucker TC, Casey G, Li L. No association between cyclooxygenase-2 and UGT1A6 genetic polymorphisms and colon cancer risk. *World J Gastroenterol* 2009; 15(18):2240-2244.
13. Phillips LS, **Thompson CL**, Plummer SJ, Tucker TC, Casey G, Li L. No association between four PTEN SNPs and colon cancer. *World J Gastroenterology* 2009; 15(30): 3771-5.
14. Nock N, Wang X, **Thompson CL**, Song Y, Baechle D, Raska P, Stein CM, Gray-McGuire C. Defining genetic determinants of the metabolic syndrome in the Framingham Heart Study using association and structural equation modeling methods. *BMC Proc* 2009; 3(suppl 7): S50.
15. **Thompson CL**, Plummer SJ, Tucker TC, Casey G, Li L. No Association of Obesity and Type 2 Diabetes Mellitus-related Genetic Variants with Colon Cancer. *Gastroenterology Research*. 2009;2(6):311-316.
16. **Thompson CL**, Plummer SJ, Tucker TC, Casey G, Li L. Interleukin-22 Genetic Polymorphisms and Risk of Colon Cancer. *Can Causes Control*. 2010; 21(8):1165-1170.
17. Ochs-Balcom HM, **Thompson CL**, Plummer S, Luo G, Tucker TC, Casey G, Li L. A RecQ protein-like 5 haplotype is associated with colon cancer in a case control study. *Gastroenterology Research*. 2010; 3(3): 101-105.
18. Nock NL, Patrick-Melin A, Cook M, **Thompson CL**, Kirwan JP, Li L. Higher Bone Mineral Density is Associated with a Decreased Risk of Colorectal Adenomas. *Int J Cancer*. 2011; 129(4):956-64.
19. **Thompson CL**, Larkin EL, Patel S, Berger NA, Redline S, Li L. Short duration of sleep increases risk of colorectal adenoma. *Cancer* 2011;117(4):841-7. **(highly cited article)**
20. Nock NL, Plummer SJ, **Thompson CL**, Casey G, Li L. FTO Polymorphisms are Associated with Adult Body Mass Index (BMI) and Colorectal Adenomas in African-Americans. *Carcinogenesis* 2011 32(5):748-56.
21. Ortiz AP, **Thompson CL**, Chak A, Berger N, Li L. Insulin Resistance, Central Obesity and Colorectal Adenomas. *Cancer* 2011; 118(7):1774-81.
22. Greer KB, **Thompson CL***², Brenner L, Bednarchik B, Dawson D, Willis J, Grady WM, Falk GW, Cooper GS, Li L, Chak A. Association of Insulin and Insulin-Like Growth Factors with Barrett's Oesophagus. *Gut* 2012; 61(5):665-72.
23. **Thompson CL**, Berger NA, Chak A, Li L. Racial Differences in Measures of Obesity and Risk of Colon Adenoma. *Obesity* 2012; 20(3):673-7.
24. Blake-Gumbs L†, Chen Z, **Thompson CL**, Berger NA, Tucker TC, Li L. Body Mass Index Change, Hormone Replacement Therapy Use and Risk of Colon Cancer in Postmenopausal Women. *J. Obes* 2012; 2012:857510.
25. **Thompson CL**, Li L. Association of Sleep Duration and Breast Cancer OncotypeDX Recurrence Score. *Breast Cancer Res Treat* 2012; 134(3):97-103.
First and corresponding author on first manuscript to demonstrate association of short sleep and breast cancer aggressiveness
26. Lin P-Y, Cheng K-L, McGuffin-Cawley JD, Shieu F-S, Samia AC, Gupta S, Cooney M, **Thompson CL***³, Liu CC. Detection of alpha-methylacyl-CoA racemase (AMACR), a biomarker of prostate cancer, in patient blood samples using a nanoparticle electrochemical biosensor. *Biosensors* 2012; 2(4): 377-87.
27. Taylor MA, Sossey-Alaoui K, **Thompson CL***¹, Danielpour D, Schiemann WP. TGF-β-mediated upregulation of miR-181a promotes breast cancer metastasis by targeting the pro-apoptotic protein Bim. *J. Clin Invest*. 2013; 123:150-63. **(highly cited article)**
28. Morton M†, **Thompson CL**. Decreasing 25-hydroxy-vitamin D Account for Portion of the Effect of Increasing Body Mass Index on Breast Cancer Mortality. *Molecular Nutrition and Food Res* 2013; 57: 260-6.
29. Leidner R, Li L, **Thompson CL**. Dampening Enthusiasm for Circulating microRNA in Breast Cancer. *Plos One* 2013; 8(3):e57841. **(highly cited article)**
30. Ochs-Balcom HM, Preus L, Wactawski-Wende J, Nie J, Johnson N, Zakharia F, Tang H, Ambrosone C, Carlson C, Carty C, Chen Z, Hutter C, Jackson RD, Kaplan R, Kooperberg C, Li L, Liu S, Neuhaus M, Peters U, Risch N, Robbins J, Seldin M, **Thompson CL**, Sucheston LE. Admixture mapping of DXA-derived phenotypes in African American women in WHI SHARe. *J Clin Endocrinol Metab* 2013; 98(4):E713-7.
31. **Thompson CL**, Fink S, Lutterbaugh JD, Elston, RC, Veigl ML, Li L, Markowitz SM. Genetic Variation in 15-Hydroxyprostaglandin Dehydrogenase and Colon Cancer Susceptibility. *Plos One* 2013; 8(5):e64122.
32. Vaughn CM, Ochs-Balcom HM, Nie J, Chen Z, **Thompson CL**, Tracy R, Li L. No Association between Circulating Levels and Genetic Variants of IL-6 and TNF-α and Colon Adenoma. *Gastroenterology Res* 2013; 6(2):43-8.

33. Helmus D†, **Thompson CL**, Zelenskiy S, Tucker TC, Li L. Red meat-derived heterocyclic amines increase risk of colon cancer: a population-based case-control study. *Nutrition and Cancer* 2013; 65(10).
34. Khawaja A†, Rao S†, Li L, **Thompson CL**. Sleep Duration and Breast Cancer Phenotype. *Journal of Cancer Epidemiology* 2013; 2013:467927.
35. Ochs-Balcom HM, Vaughn CB, Nie J, Chen Z, **Thompson CL**, Parekh N, Tracy R, Li L. Racial differences in the association of insulin-like growth factor pathway and colon adenoma risk. *Cancer Causes and Control* 2014; 25(2):161-70.
36. Elliot RM, Shenk RR, **Thompson CL***2, Gilmore HL. Touch preparations for the intraoperative evaluation of sentinel lymph nodes after neoadjuvant therapy in breast cancer patients have a high false negative rate. *Arch Pathol Lab Med* 2014; 138 (6): 814-8.
37. Zelenskiy S†, **Thompson CL**, Tucker TC, Li L. High Dietary Glycemic Load is Associated with Increased Risk of Colon Cancer. *Nutr Cancer* 2014; 66(3):362-8.
38. Sossey-Alaoui K, Pluskota E, Davuluri R, Bialkowska, Das M, Szpak D, Lindner D, Downs-Kelly E, **Thompson CL***1, Plow EF. Kindlin-3 enhances breast cancer progression and metastasis by activating TWIST-mediated angiogenesis. *FASEB J* 2014; 28(5):2260-71.
39. Morton M†, Bai X, Merry C, Khalil AM, Leidner R, **Thompson CL**. Identification of mRNAs and lincRNAs associated with lung cancer progression using next-generation RNA sequencing from laser micro-dissected archival FFPE tissue specimens. *Lung Cancer* 2014; 85(1):31-9.
40. Sizemore S, Sizemore GM, Booth CN, **Thompson CL***3, Silverman P, Bebek G, Abdul-Karim FW, Avril S, Keri RA. Hypomethylation of the MMP7 Promoter and Increased Expression of MMP7 Distinguishes the Basal-like Breast Cancer Subtype from other Triple Negative Tumors. *Breast Cancer Res Treat.* 2014; 146(1):25-40.
41. Ochs-Balcom HM, Cannioto R, Nie J, Millen AE, Freudenheim JL, Chen Z, **Thompson CL**, Tracy R, Li L. Adipokines do not Mediate the Association of Obesity and Adenomatous Polyps. *J. Cancer Epidemiol.* 2014; 2014:371254.
42. **Thompson CL**, Owusu C, Nock NL, Li L, Berger NA. Race, age and obesity disparities in adult physical activity levels in breast cancer patients and controls. *Front Public Health* 2014;2:150.
43. Kenison TC†, Silverman P, Sustin M, **Thompson CL**. Differences between Nurse Practitioner and Physician Care Providers on Rates of Secondary Cancer Screening and Discussion of Lifestyle Factors in Breast Cancer Survivors. *J Cancer Survivorship* 2015; 9(2):223-9.
44. Qin A, **Thompson CL***2, Silverman P. Predictors of late onset heart failure in breast cancer patients treated with doxorubicin. *J Cancer Survivorship* 2015;9(2):252-9.
45. Abola M, **Thompson CL**, Chen Z, Chak A, Berger NA, Kirwan JP, Li L. Serum Levels of Retinol-Binding Protein 4 (RBP4) and Risk of Colon Adenoma. *Endocrine-Related Cancer* 2015; 22(2):L1-4.
46. Bomeisl PE, **Thompson CL***2, Harris LH, Gilmore HL. Comparison of OncotypeDX Recurrence Score by Histologic Subtypes of Breast Carcinoma. *Archives of Pathology and Laboratory Medicine* 2015; 139 (12):1546-9.
47. Bai S†, Shenk R, **Thompson C***2, Plecha D. Improving Accuracy of Axillary Lymph Node Surgery in Breast Cancer with Ultrasound Guided Needle Localization of Previously Biopsied Lymph Nodes. *Ann Surg Oncol* 2015; 22(13):4241-6.
48. Merry CR, McMahon S, **Thompson CL***3, Miskimen K, Harris L, Khalil AM. Integrative transcriptome-wide analyses reveal critical HER2-regulated lincRNAs and mRNAs in HER2+ Breast Cancer. *Breast Cancer Res Treat* 2015; 150 (2):321-34.
49. Su K-H, Hu L Stehning C, Helle M, Qian P, **Thompson CL***2, Periera GC, Jordon DW, Herrmann KA, Traughber M, Traughber BJ, Muzic RF. Generation of brain pseudo-CTs using an undersampled, single-acquisition UTE-mDixon pulse sequence and unsupervised clustering. *Medical Physics* 2015; 42(8):4974.
50. Zhang Y, Janyasupab M, Liu CW, Cai J, Popa A, Samia AC, Wang KW, Zu J, Schiemann W, **Thompson CL***1, Liu CC. Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of breast cancer metastasis, using human blood and urine samples. *Recent Patents on Biosensors* 2015; 5(2): 93-100.
51. Vyas R, **Thompson CL***2,3, Zargar H, Selph J, Gerstenblith M. Epidemiology of Genitourinary Melanoma in the United States: 1992-2012. *JAAD* 2016;75(1):144-50.
52. Wan T, Block NB, Plecha D, **Thompson CL***1, Gilmore H, Jaffe C, Harris L, Madabhushi A. A Radiogenomics Approach for Identifying High Risk Estrogen Receptor-positive Breast Cancers on DCE-MRI: Preliminary Results in Predicting OncotypeDX Risk Scores. *Nature Scientific Reports* 2016; 6:21394.
53. Scott JF, **Thompson CL***2,3, Vyas R, Honda K, Zender C, Rezaee R, Lavertu P, Koon H, Cooper KD, Gerstenblith M. Parotid Melanoma of Unknown Primary. *J Can Res Clin Oncol* 2016; 142 (7):1529-37.
54. Okuku F, Orem J, Holoya G, De Boers C, **Thompson CL***2,3, Cooney M. Prostate Cancer Burden at the Uganda Cancer Institute (UCI). *J Global Oncology* 2016 (in press).
55. Tran D, Gotow E, Galvin J, Bordeaux JS, **Thompson CL***2, Cooper KD, Gerstenblith MR. Meta-Analyses of Associations between Cutaneous Melanoma and Thyroid Cancer. *J Clin Exp Derm* 2016; 7:343.

56. Kibria G, Ramos E, Lee K, Bedoyan S, Huang S, Samaeekia R, Athman J, Harding C, Lotvall J, Harris L, **Thompson CL***¹, Liu H. A rapid, automated surface protein profiling of single circulating exosomes in human blood. *Sci Rep* 2016;6:36502.
57. Radhakrishnan A†, Silverman P, Pollack CD, Pfoh ER, Shenk R, **Thompson CL**. Understanding Age and Race Disparities in the Application of Sentinel Lymph Node Biopsy in Breast Cancer. *J Investig Med* 2016;64(8):1241-1245.
58. Merry CR, McMahon S, **Thompson CL***³, Khalil AM. Transcriptome-wide identification of mRNAs and lincRNAs associated with Trastuzumab Resistance in HER2-positive breast cancer. *Oncotarget* 2016; 7(33):53230-53244.
59. Morrison CD, Allington TM, **Thompson CL***², Gilmore HL, Chang JC, Keri RA, Schiemann WP. c-Abl Inhibits Breast Cancer Tumorigenesis through Reactivation of p53-mediated p21 Expression. *Oncotarget* 2016; 7(45):72777-72794.
60. Garlick C, **Thompson C***², Dubchuck C, Constantinou N, Plecha D. Comparing cancer detection rates of patients undergoing short term follow-up vs routine follow-up after benign breast biopsies, is follow-up needed? *Clin Imaging* 2017; 42:37-42.
61. Somasegar S†, Li L, **Thompson CL**. No Association of Reproductive Risk Factors with Breast Cancer Tumor Grade. *Eur J Can Prev* 2017; 5(2).
62. Gupta N†, Li L, **Thompson CL**. The Association of Inherited Variation in the CLOCK Gene with Breast Cancer Tumor Grade. *Fam Med and Comm Health* 2017; 5(2): 103-8.
63. Soucise A, Vaughn C, **Thompson CL**, Millen AE, Freudenheim JL, Wactawski-Wende J, Phipps A, Hale L, Qi L, Ochs-Balcom HM. Sleep quality, duration and breast cancer aggressiveness. *Breast Cancer Res Treat* 2017; 164(1): 169-178.
64. Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, Xu H, Ogurtsova A, Anders RA, Fischer AH, Kraft S, Gerstenblith MR, **Thompson CL***¹, Hona K, Cuda JD, Eberhart CG, Handa JT, Lipson EJ, Taube JM. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. *Lab Invest* 2017; 97(9):1063-71.
65. Tsung K, **Thompson CL**, Knight JM, Maximuk S, Sadri N, Gilmore H, Keri RA, Vinayak S, Harris L, Silverman P. A Breast Multidisciplinary Genomic Tumor Board is Feasible and Can Provide Timely and Impactful Recommendations. *Breast J* 2018; 24(4):676-7.
66. Allan K†, Berger NA, Li L, **Thompson CL**. Short Sleep as a Contributor to Racial Disparities in Breast Cancer Tumor Grade. *Fam Med and Comm Health* 2017; 5(2):149-54.
67. Arbesman J, Ravichandran S, Funchain P, **Thompson CL**. Melanoma Cases demonstrate increased carrier frequency of Phenylketonuria/hyperphenylalanemia mutations. *Pig Cell Mel Res* 2018; 31(4):529-33.
68. Obayo S, Orem J, **Thompson CL***², Cooney MM. Clinical Presentation and Treatment Outcomes of Esophageal Cancer Patients at the Uganda Cancer Institute (UCI). *J Global Oncology* 2018; (in press).
69. Scott JF, Conic R, **Thompson CL***², Gerstenblith MR, Bordeaux JS. Stage IV Melanoma of Unknown Primary: A Population-Based Study in the United States from 1973 to 2014. *J Am Acad Dermatol* 2018; 79(2):258-65.
70. Gorlov I, Orlov I, Ringelberg C, Hernando E, Ernstoff MS, Cheng C, Her S, Parker JS, **Thompson CL***¹, Gerstenblith MR, Berwick M, Amos C. Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics. *Melanoma Res* 2018; 58(5):380-9.
71. Bakshi S, Schmidt HM, Baskin AE, Croniger CM, **Thompson CL***², Bonfield T, Fletcher D, Berger NA. Sexual Dimorphism in Developmental and Diet Dependent Circulating Retinol Binding Protein 4. *Obesity Science and Practice* 2018; 4(6):526-34.
72. Stepanek T†, Constantinou N, Pham R, Marshall H, **Thompson C***^{2,3}, Plecha D. Changes in the utilization of the BI-RADS category 3 assessment in recalled patients before and after the implementation of screening digital breast tomosynthesis. *Acad Radiol* 2019; 26(11):1515-25.
73. Alencherry E†, Goel, R, Gore S, **Thompson C***^{2,3}, Dubchuk C, Plecha D. Clinical, imaging, and intervention factors associated with the upgrade of isolated flat epithelial atypia. *Clin Imaging* 2019; 54:21-4.
74. Darrow CJ†, Bai-Tong SS, Kang EM, **Thompson CL***^{2,3}, Walsh MC. Use of Acidified Versus Non-Acidified Liquid Human Milk Fortifier in Very Low Birth Weight Infants: A Retrospective Comparison of Clinical Outcomes. *J Neonatal Perinatal Med* 2020;13(1):71-79.
75. Zhao F, Heo JU, Jones R, Zheng J, Qian P, Baydoun A, Kuo J-W, al Helo R, **Thompson C***², Avril N, DeVincent D, Hunt H, Gupta A, Traughber B. Abdominal-Pelvis MR to CT registration using a synthetic CT intermediate. *Artificial Intelligence in Medicine* 2020 (in press).
76. Scott JF, Brough KR, Grigoryan KV, Muzic JG, Kim GY, Conic R, Tsai S, Brewer JD, Baum CL, Litzow MR, Hogan WJ, Patnaik MS, Hashmi SK, Lazarus HM, Bordeaux JS, **Thompson CL***^{2,3}, Gerstenblith MR, Lehman JS. Risk factors for keratinocyte carcinoma in recipients of allogeneic hematopoietic cell transplantation recipients. *JAMA Dermatol* 2020;156(6):1-9.
77. Walsh RS†, Payne A, Cossler NJ, **Thompson CL***², Bholra M. Safety of immediate skin-to-skin contact after vaginal birth in vigorous late preterm neonates – A pilot study. *Neonatal Perinatal Med* 2020; (in press).

78. Okello CD, Mulumba Y, Omoding A, Ddungu H, Welch K, **Thompson CL***², Orem J, Cooney MM. Characteristics and Outcomes of Patients with Multiple Myeloma at the Uganda Cancer Institute. *African Health Sciences* 2020 (in press).

Recently submitted

1. Nguyen M-T†, Krach J†, Knight J, **Thompson CL**. Perceived Risk of Breast Cancer and God Health Locus of Control in High Risk White and African American Women. *J Psychosocial Oncology* (under review).
 2. Li S†, **Thompson CL**. Association of Family History of Other Cancers with Risk of Breast Cancer: A Meta-Analysis of Case-Control Studies. *Br J Cancer* (submitted).
 3. Elkins JM, Campos SC, **Thompson CL***², Mohseni MM, Sheele JM. Analysis of Male Emergency Department Patients infected with Gonorrhea or Chlamydia. Sexually Transmitted Diseases (submitted).
 4. Freyvogel-Ramirez, M†, **Thompson C***², Plecha D. False Negative Rate of Percutaneous Axillary Lymph Node Bias in Breast Cancer Patients. *Ann Surg Onc* (submitted).
 5. Kar S, ... **Thompson C***¹...et al. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies new candidate susceptibility genes for breast and ovarian cancer. *Cancer Res* (submitted).
 6. Miller ME, Patil N, Li P, Freyvogel M, Greenwalt I, Rock L, Simpson A, Teresczuk M, Carlisle S, Penuela M, **Thompson CL***³, Shenk R, Dietz J. Hospital System Initial Experience with Stainless Steel Magnetic Seeds for Breast and Lymph Node Localization. *Annals of Surg Onc* (submitted).
 7. Fish R†, **Thompson C***², Weber A, March M, Crowley M, Voos K. Early antenatal counseling in the outpatient setting for high-risk pregnancies: A randomized controlled trial. *J Perinatology* (submitted).
- †Student or fellow mentees that published manuscripts from the project that I mentored them on

*Team Science Contributions: On these manuscripts I served in a key role as the cancer translational researcher, lending my expertise in clinical/epidemiology study design and/or statistical analysis. For these I have contributed one or more of the following: ¹specific patient samples and/or data; ²biostatistical support; ³study design and/or epidemiology expertise.

Invited, Non-Peer Reviewed

1. O'Neill SC, **Thompson CL**, Graves KD, Kapp JM, Worthington JL, Madlensky L. Job satisfaction in cancer prevention and control: a survey of the American Society of Preventive Oncology. *Cancer Epidemiol Biomarkers Prev*. 2010; 19(8):2110-2.
2. Sprague BL, **Thompson CL**, Ganz PA, Kanetsky PA, Kushi LH, Nebeling L. The Business of Research: Budgets, Personnel, Planning, and Pitfalls – a Report from the American Society of Preventive Oncology's Junior Members Interest Group. *Cancer Epidemiol Biomarkers Prev*. 2011;20(8):1802-4.

Book Chapters

1. **Thompson CL**, Li L. Sleep Disorders and Cancer Risk. *Impact of Sleep and Sleep Disturbances on Obesity and Cancer*. 2013.
2. **Thompson CL**, Varadan V. Clinical Applications of Next-Generation Sequencing of Formalin-Fixed Paraffin-Embedded Tumors. *Next Generation Sequencing in Cancer Research Volume 2*. 2015.
3. Prabhakar D, **Thompson CL**, Harris L. Blood Markers for Breast Cancer Management. *Molecular Pathology of Breast Cancer*. 2015.
4. Liu CC, Zhang Y, Janyasupab M, **Thompson CL**, Yen Y. Single-Use, Disposable, *in vitro* Biosensors for the Detection of Biomarkers of Various Diseases. *Annals of Biomedical Engineering*, 2016.
5. **Thompson CL**, Reece M†. Adipokines in Prostate Cancer. *Energy Balance and Prostate Cancer*. 2017.
6. Ashton K, **Thompson CL**. Did Cancer Kill My Sleep? *Sleep Disorders: A Case a Week from the Cleveland Clinic*. 2019.

Nationally Presented Abstracts

- Presented 22 abstracts nationally as first author
- Eight abstracts presented nationally by student/mentee (with me as senior author)
- Co-authored 30+ abstracts presented by collaborators as a team scientist